Latest News

Boehringer walks away from CureVac deal

© CureVac AG


by um

Setback for CureVac: Boehringer Ingelheim halts a 7-year-old €500m lung cancer collaboration with the Tübingen-based biopharmaceutical company.

CureVac announced the termination of the 2014 programme BI1361849 in its financial report. Seven years ago, CureVac had received €35m upfront, with the promise of up to €430m in milestone payments. The collaboration aimed to investigate CureVac’s therapeutic mRNA vaccine in combination with Boehringer Ingelheim’s own tyrosine kinase inhibitor afatinib in non-small lung cancer (NSCLC). The programme applies an “older protamine formulation technology, which reflected the state of the technology development at the time”, CureVac said. Now, Boehringer Ingelheim wants to pull out of the programme.

There is a Phase 1/2 clinical trial in NSCLC applying BI1361849 as a combination therapy ongoing. The two companies are now weighing their options for the future of their collaboration.

The termination will become effective in November 2021.

German HTGF IV fund closes at €493m

Alongside the Federal Ministry of Economics and Climate Protection (BMWK) and KfW Capital, 45 private investors (companies) participated in HTGF IV...

DiogenX SA raises €27.5M in Series A financing

The Marseille-based specialist for beta cell regeneration announced it want to use the proceeds to advance its first-in-class regenerative treatment...

VarmX BV raises €30m in Series B2 financing

VectivBio taken over in $1bn acquisition

VectivBio Holding AG has entered into a acquisition agreement with Ironwood Pharmaceuticals Inc. Ironwood will launch a tender offer to buy...

LSP Dementia Fund closes at €260m

Investors included the Alzheimer’s Association, the European Investment Fund EIF, several unnamed global pharmaceutical, and insurance companies,...

Mainz Biomed Partners with Microba Life Sciences

Leveraging a platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases, Microba and Mainz Biomed...

Neogap Therapeutics A/S partners with Cellerys AG

Stockholm based Neogap Therapeutics AB has partnered with Zurich-based Cellerys AG to provide its EpiTCer®  platform within Celleris upcoming...